BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/23/2025 6:48:59 AM | Browse: 217 | Download: 597
Publication Name World Journal of Clinical Oncology
Manuscript ID 108955
Country Brazil
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Minireviews
Article Title Neoadjuvant treatment in resectable pancreatic cancer: Why is upfront surgery so hard to be beaten?
Manuscript Source Invited Manuscript
All Author List Pedro Luiz Serrano Uson Junior, Kunal C Kadakia and Raphael L C Araujo
ORCID
Author(s) ORCID Number
Pedro Luiz Serrano Uson Junior http://orcid.org/0000-0001-6122-1374
Raphael L C Araujo http://orcid.org/0000-0002-7834-5944
Funding Agency and Grant Number
Corresponding Author Raphael L C Araujo, Adjunct Professor, FACS, MD, PhD, Department of Surgery, Universidade Federal de São Paulo, R. Napoleão de Barros, 715, São Paulo 04024-002, São Paulo, Brazil. raphael.l.c.araujo@gmail.com
Key Words Pancreas cancer; Neoadjuvant treatment; Chemotherapy; Radiation Therapy; Surgery; Pancreatectomy
Core Tip Upfront surgery remains essential for patients with truly resectable tumors since surgery followed by adjuvant therapy is evidence-based and should not be abandoned. Moreover, current neoadjuvant treatment for resectable lesions with FOLFIRINOX is insufficient due to poor survival outcomes. Better systemic approaches are needed, and germline testing and precision medicine hold promise but are actionable in only a minority of cases, molecular subtyping should be incorporated into future trial designs.
Publish Date 2025-09-23 06:48
Citation

Uson Junior PLS, Kadakia KC, Araujo RLC. Neoadjuvant treatment in resectable pancreatic cancer: Why is upfront surgery so hard to be beaten? World J Clin Oncol 2025; 16(9): 108955

URL https://www.wjgnet.com/2218-4333/full/v16/i9/108955.htm
DOI https://dx.doi.org/10.5306/wjco.v16.i9.108955
Full Article (PDF) WJCO-16-108955-with-cover.pdf